Spherix Analyzes Reviews of gMG Therapies, Vyvgart, Ultomiris
Neurologists find both Vyvgart (efgartigimod) and Ultomiris (ravulizumab-cwvz) effective for treating generalized myasthenia gravis (gMG), but believe Ultomiris has a more convenient dosing schedule while Vyvgart may have a better safety profile. That’s according to a recent analysis by the market intelligence firm Spherix Global Insights. Spherix’s analysis of the two treatments was part of Launch Dynamix, a service that provides […]
Argenx’s Vyvgart and Alexion’s Ultomiris Go Toe-to-Toe in Generalized Myasthenia Gravis, According to Spherix Global Insights
Positive perceptions for both brands will drive expansion of patient share and prescriber base EXTON, Pa., August 24, 2022/ PRNewswire/ – Competition in the generalized myasthenia gravis (gMG) market is heating up with the launches of argenx’s Vyvgart and Alexion’s Ultomiris earlier this year. Both brands have the same approved indication but differ on mechanism […]
New Spherix Data in Alzheimer’s Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As Well As Novo Nordisk’s Semaglutide
New Spherix Data in Alzheimer’s Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As Well As Novo Nordisk’s Semaglutide Differentiation amongst these pipeline agents will hinge on ease of access, easy-to-use companion diagnostics, and safety EXTON, Pa., July 2022 – Despite multiple high-profile trial failures in early Alzheimer’s disease […]
Biohaven’s Nurtec ODT and AbbVie’s Qulipta Emerging as the Top Two Contenders in the Preventive Migraine Space, According to Spherix Global Insights
Growth of newer market entrants resulting in relatively flat projected share for Eli Lilly’s Emgality, Teva’s Ajovy, and Amgen’s Aimovig EXTON, Pa., June 10, 2022 /PRNewswire – According to the latest deep dive report included in Spherix’s Launch Dynamix™: Qulipta for Migraine Prevention (US) service, surveyed neurologists and migraine specialists report high satisfaction with AbbVie’s Qulipta […]
Vyvgart’s Novel Mechanism of Action and Efficacy Are Top Advantages of the Brand, According to Neurologists Surveyed by Spherix Global Insights
Data suggest potential competitive edge over Alexion’s Soliris on multiple treatment metrics EXTON, Pa., June 9, 2022 / PRNewswire/ — Three months into the launch of argenx’s Vyvgart for generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor antibody (ACh-R) positive, neurologists identified (unaided) the brand’s novel mechanism of action as the first neonatal […]
Spherix Global Insights Announces Fielding of New Research Geared Towards Fellows and Residents in Immunology, Neurology, Nephrology, and Ophthalmology
The project is designed to explore to what degree the next generation of specialists are prepared to enter clinical practice and what baseline opinions will they be bringing as they move from a training environment into real world patient management EXTON, Pa., June 7, 2022 /PRNewswire/ — Fellows will be the next generation of practitioners. […]
Mayzent and Kesimpta Gaining Ground as MS Treatments in Canada
Novartis’ Mayzent (siponimod) and Kesimpta (ofatumumab) are gaining ground among multiple sclerosis (MS) therapies in Canada, according to the latest Spherix Global Insights’ report. “Following an eventful 2021 that included the launch of two new brands — Novartis’ Kesimpta and BMS’ Zeposia — and generic versions of Biogen’s Tecfidera, the Canadian multiple sclerosis (MS) market appears to be settling into patterns […]
Novartis’ Multiple Sclerosis Brands Mayzent and Kesimpta Both Show Strong Growth in Canada
Despite a negative CDEC1 reimbursement recommendation, BMS’ Zeposia has seen notable growth in the past six months, with neurologists optimistic about the future EXTON, Pa., May 26, 2022/PRNewswire – Following an eventful 2021 that included the launch of two new brands—Novartis’ Kesimpta and BMS’ Zeposia—and generic versions of Biogen’s Tecfidera, the Canadian multiple sclerosis (MS) […]
Neurologists’ React to CMS’ Finalized NCD Decision on Anti-Amyloid Monoclonal Antibodies for Alzheimer’s Disease
Spherix captures potential impact on Eisai/Biogen’s lecanemab, Eli Lilly’s donanemab, and Roche/Genentech’s gantenerumab EXTON, Pa., / May 16, 2022 / 6PRNewswire – On April 7, 2022, CMS finalized its NCD for anti-amyloid monoclonal antibodies (mAbs) for the treatment of Alzheimer’s disease. Given the importance of this decision on the burgeoning treatment landscape, Spherix surveyed 81 […]
Novartis’ Kesimpta is Poised for Strong Growth in the European Multiple Sclerosis Market, Spherix Global Insights Reports
Favorable reimbursement decisions for Ponvory may accelerate uptake for the Janssen brand EXTON, Pa., April 5, 2022 / PRNewswire / — Spherix Global Insights, a leading market intelligence firm specializing in neurology-based research and insights, has been tracking the multiple sclerosis (MS) market in Europe through their RealTime Dynamix™: Multiple Sclerosis (EU) service since 2017. […]
